Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Atossa Therapeutics, Inc. (ATOS : NSDQ)

• Company Description    Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company develops medicines in areas of significant unmet medical need in oncology principally in the United States. Its lead drug candidate is oral (Z)-endoxifen. Atossa Therapeutics Inc., formerly known as Atossa Genetics Inc., is based in Seattle, Washington. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $2.52 Daily Weekly Monthly 20 Day Moving Average: 57,085 shares Shares Outstanding: 9.98 (millions) Market Capitalization: $25.10 (millions) Beta: 1.27 52 Week High: $19.35 52 Week Low: $1.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.57% 7.33% 12 Week 13.29% 10.89% Year To Date -71.57% -74.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1448 NW Market Street Suite 500 - SEATTLE,WA 98107 USA ph: 206-588-0256 fax: 206-430-1288 ir@atossatherapeutics.com http://www.atossatherapeutics.com

• General Corporate Information    Officers Steven C. Quay - Chief Executive Officer;Chairman; President Mark J. Daniel - Chief Financial Officer Richard I. Steinhart - Director Shu-Chih Chen - Director Jonathan F. Finn - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04962H704 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 9.98 Most Recent Split Date: 2.00 (0.07:1) Beta: 1.27 Market Capitalization: $25.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.92 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.94 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.81 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 9.48% vs. Previous Quarter: 14.41% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -102.99 03/31/26 - -84.91 12/31/25 - -65.56 ROA 06/30/26 - -85.78 03/31/26 - -72.36 12/31/25 - -57.74 Current Ratio 06/30/26 - 5.69 03/31/26 - 4.92 12/31/25 - 5.53 Quick Ratio 06/30/26 - 5.14 03/31/26 - 4.92 12/31/25 - 5.53 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 3.12 03/31/26 - 3.54 12/31/25 - 4.57 Inventory Turnover 06/30/26 - 0.00 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©